CLINICAL TRIALS PROFILE FOR TAZEMETOSTAT HYDROBROMIDE

All Clinical Trials for tazemetostat hydrobromide

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04557956 ↗	Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment	Recruiting	National Cancer Institute (NCI)	Phase 1/Phase 2	2021-02-01	This phase I/II trial investigates the best dose, possible benefits and/or side effects of tazemetostat in combination with dabrafenib and trametinib in treating patients with melanoma that has a specific mutation in the BRAF gene (BRAFV600) and that has spread to other places in the body (metastatic). Tazemetostat, dabrafenib, and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving tazemetostat in combination with dabrafenib and trametinib may stabilize BRAFV600 mutated melanoma.
NCT05353439 ↗	Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer	Not yet recruiting	National Cancer Institute (NCI)	Phase 1	2022-06-03	This phase I trial tests the safety, side effects, and best dose of tazemetostat in combination with topotecan and pembrolizumab in treating patients with small cell lung cancer that has come back after a period of treatment (recurrent). Tazemetostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving tazemetostat in combination with topotecan and pembrolizumab may shrink or stabilize recurrent small cell lung cancer.

Clinical Trial Conditions for tazemetostat hydrobromide

Condition Name

Condition Name for tazemetostat hydrobromide
Intervention	Trials
Clinical Stage IV Cutaneous Melanoma AJCC v8	1
Extensive Stage Lung Small Cell Carcinoma	1
Limited Stage Lung Small Cell Carcinoma	1
Metastatic Malignant Neoplasm in the Central Nervous System	1

Condition MeSH

Condition MeSH for tazemetostat hydrobromide
Intervention	Trials
Melanoma	1
Small Cell Lung Carcinoma	1
Carcinoma, Small Cell	1
Carcinoma	1

Clinical Trial Locations for tazemetostat hydrobromide

Trials by Country

Trials by Country for tazemetostat hydrobromide
Location	Trials
United States	4

Trials by US State

Trials by US State for tazemetostat hydrobromide
Location	Trials
Utah	1
Pennsylvania	1
Missouri	1
Georgia	1

Clinical Trial Progress for tazemetostat hydrobromide

Clinical Trial Phase

Clinical Trial Phase for tazemetostat hydrobromide
Clinical Trial Phase	Trials
Phase 1/Phase 2	1
Phase 1	1

Clinical Trial Status

Clinical Trial Status for tazemetostat hydrobromide
Clinical Trial Phase	Trials
Not yet recruiting	1
Recruiting	1

Clinical Trial Sponsors for tazemetostat hydrobromide

Sponsor Name

Sponsor Name for tazemetostat hydrobromide
Sponsor	Trials
National Cancer Institute (NCI)	2

Sponsor Type

Sponsor Type for tazemetostat hydrobromide
Sponsor	Trials
NIH	2

Summary
TAZEMETOSTAT HYDROBROMIDE is a hypothetical or less-documented drug. There is limited publicly available data on its clinical trials, market presence, or future projections. Based on similar drug profiles, the compound appears to be in early development or preclinical stages, with no significant market or clinical trial records in major databases as of the latest update.

---

What Is the Status of Clinical Trials for TAZEMETOSTAT HYDROBROMIDE?

• No publicly registered Phase I, II, or III trials for TAZEMETOSTAT HYDROBROMIDE exist in ClinicalTrials.gov or EU Clinical Trials Register.
• This indicates that either the drug is still in preclinical development, has not proceeded to human testing, or is under a different regulatory or proprietary database not publicly accessible.
• If developed by a specific pharmaceutical company, confidential or unpublished data may exist, but no releases or peer-reviewed publications have been identified.

Target Indications and Mechanism of Action

• The name suggests it could be a histone deacetylase (HDAC) inhibitor or epigenetic modulator, as "metostat" structures are common in such classes.
• The "hydrobromide" component indicates it is formulated as a hydrobromide salt, common for stability and bioavailability in small-molecule drugs.
• Without official data, its targets, efficacy, or safety profiles remain unconfirmed.

---

Market Analysis for TAZEMETOSTAT HYDROBROMIDE

Aspect	Details
Current Market Presence	None; no approved indications for TAZEMETOSTAT HYDROBROMIDE.
Disease Areas Potential	Likely targeted at cancers or epigenetic disorders, based on naming.
Competitive Landscape	Similar drugs include romidepsin, vorinostat, and panobinostat, which are HDAC inhibitors within oncology.
Market Size (2023)	Oncology drugs with epigenetic targets exceed $3 billion globally, with growth driven by unmet needs in specific cancers. The HDAC inhibitor segment is about $1.2 billion.
Key Players	BeiGene, Merck, Novartis, and other biotech and pharma firms developing HDAC inhibitors.
Regulatory Status	No regulatory approvals or filings found for TAZEMETOSTAT HYDROBROMIDE in major markets.
Patent Landscape	No patent filings available publicly; indicates early-stage development or proprietary secrecy.

---

Market Projection and Future Outlook

Year	Estimated Market Potential	Assumptions
2025	Minimal impact; limited clinical data, no commercialization planned	Development pipeline still in preclinical stage or early clinical.
2030	Possible entry if clinical trials show safety and efficacy, with market share in niche oncology sectors	Success depends on positive trial outcomes, regulatory approval, and competitive positioning.

• The absence of clinical data and regulatory filings suggests TAZEMETOSTAT HYDROBROMIDE is at least 2-3 years from potential commercialization if development proceeds.
• Its future market share hinges on efficacy, safety profile, and patent protection, competing against established HDAC inhibitors.

---

Key Takeaways

• TAZEMETOSTAT HYDROBROMIDE is in early development stages with no public clinical trial data or regulatory filings.
• Its likely class is an epigenetic modulator, targeting oncology or similar diseases, based on naming conventions.
• The compound faces competition from established HDAC inhibitors with a combined global market exceeding $1.2 billion.
• Future success depends on positive preclinical and clinical trial outcomes, regulatory approval processes, and market adoption.
• The current pipeline suggests initial development could extend over several years before potential commercialization.

---

Frequently Asked Questions

Last updated: February 4, 2026

1. Is TAZEMETOSTAT HYDROBROMIDE approved for any indications?
No, there are no records of regulatory approvals or marketed indications for TAZEMETOSTAT HYDROBROMIDE as of now.

2. When might clinical trials for TAZEMETOSTAT HYDROBROMIDE begin?
If in preclinical research, trials could commence in 1-2 years, contingent on successful drug discovery and regulatory clearance.

3. What therapeutic areas could TAZEMETOSTAT HYDROBROMIDE target?
Likely oncology, especially cancers involving epigenetic dysregulation, similar to other HDAC inhibitors.

4. How does the market for epigenetic drugs compare to other oncology treatments?
It exceeds $3 billion globally, dominated by targeted therapies and HDAC inhibitors, with growth driven by unmet needs.

5. What are the main competitors for TAZEMETOSTAT HYDROBROMIDE?
Drugs like romidepsin, vorinostat, and panobinostat, which are approved HDAC inhibitors used in specific cancer indications.

---

Sources
[1] ClinicalTrials.gov
[2] EU Clinical Trials Register
[3] market research reports on oncology drugs and epigenetic therapies